Literature DB >> 8607677

Repair of coarctation of the aorta in adults: the fate of systolic hypertension.

W J Wells1, T W Prendergast, F Berdjis, D Brandl, P E Lange, R Hetzer, V A Starnes.   

Abstract

BACKGROUND: The benefit of coarctation repair in adults has been questioned by suggesting that hypertension may not be relieved by the operation and that surgical intervention may have no impact on the natural history of the disease.
METHODS: To delineate the impact of surgical intervention on systolic hypertension, we conducted a retrospective review of 26 adults with a mean age of 32 +/- 10 years who underwent coarctation repair between 1987 and 1993. All patients were hypertensive (mean systolic blood pressure, 174 +/- 21 mm Hg; range, 140 to 220 mm Hg), and 18 patients (69%) were on a regimen of at least one hypertensive medication at the time of surgical admission. All patients underwent catheterization, and the mean peak systolic gradient across the coarctation was 61 +/- 25 mm Hg (range, 25 to 120 mm Hg). Operation included resection and end-to-end anastomosis (3 patients), resection with an interposition tube graft (6 patients), a bypass graft (11 patients), and patch angioplasty (6 patients). There was no hospital mortality or late morbidity.
RESULTS: Intermediate follow-up was available at a mean of 2.3 +/- 2 years (range, 1 to 7 years). At last follow-up, the peak systolic gradient between the upper and lower body was trivial (< or = 10 mm Hg) in 23 patients (88%) and mild (11 to 20 mm Hg) in 3 (12%). All patients had significant improvement in systolic blood pressure (p < 0.001) compared to preoperative values, and the majority (23, 88%) were normotensive. More than half of the patients (14, 54%) were still on a regimen of antihypertensive medication at last follow-up, with a trend (p = 0.06) toward older patients requiring medication.
CONCLUSIONS: Surgical repair of coarctation in adults is an effective, low-risk procedure, which results in a significant improvement in systolic hypertension and a decreased requirement of antihypertensive medications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607677     DOI: 10.1016/0003-4975(96)00008-2

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Complete aortic arch obstruction: interruption or aortic coarctation?

Authors:  J W J Vriend; J Lam; B J M Mulder
Journal:  Int J Cardiovasc Imaging       Date:  2004-10       Impact factor: 2.357

2.  Treatment of aortic coarctation in adolescence. A bottleneck resolved with a "growing" stent?

Authors:  C A Nienaber; H Ince
Journal:  Z Kardiol       Date:  2005-02

3.  Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan's syndrome.

Authors:  Candice K Silversides; Marla Kiess; Luc Beauchesne; Timothy Bradley; Michael Connelly; Koichiro Niwa; Barbara Mulder; Gary Webb; Jack Colman; Judith Therrien
Journal:  Can J Cardiol       Date:  2010-03       Impact factor: 5.223

4.  Endovascular management of coarctation of the aorta.

Authors:  D R Turner; P A Gaines
Journal:  Semin Intervent Radiol       Date:  2007-06       Impact factor: 1.513

5.  Therapy refractory hypertension in adults: aortic coarctation has to be ruled out.

Authors:  M E W Hemels; E S Hoendermis; J P van Melle; P G Pieper
Journal:  Neth Heart J       Date:  2011-02-11       Impact factor: 2.380

6.  Single-stage repair of adult aortic coarctation and concomitant cardiovascular pathologies: a new alternative surgical approach.

Authors:  Mert Yilmaz; Bulent Polat; Davit Saba
Journal:  J Cardiothorac Surg       Date:  2006-06-27       Impact factor: 1.637

7.  Prosthetic Subclavian-Aortic Bypass as a Safe Surgical Technique for the Coarctation of the Aorta in Adults.

Authors:  Ali Refatllari; Ermal Likaj; Selman Dumani
Journal:  Open Access Maced J Med Sci       Date:  2015-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.